Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-200 vs ISOVUE-370
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.
Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Intravascular administration for angiocardiography, aortography, peripheral arteriography, venography, and contrast-enhanced computed tomography (CT),Body cavity imaging: arthrography, hysterosalpingography, and fistulography
Intravascular administration for computed tomography (CT) imaging,Intrathecal administration for myelography (CT and conventional),Angiography (coronary, cerebral, peripheral, etc.),Intravenous urography,Left ventriculography,Arteriography,Other radiographic contrast procedures
Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.
Intravenous injection of 50-200 m L of Isovue-370 (iopamidol 76% solution, 370 mg I/m L) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 m L total volume.
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function (creatinine clearance >60 m L/min); prolonged to up to 30 hours in severe renal impairment.
Iopamidol is not metabolized; eliminated unchanged via glomerular filtration.
Not metabolized; eliminated unchanged via glomerular filtration.
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Primarily renal (glomerular filtration) with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% excreted in feces.
<2% bound; negligible binding to plasma proteins.
Minimal; approximately 1-5% bound to serum proteins (primarily albumin).
0.24 L/kg; restricted to extracellular fluid, no intracellular penetration.
Volume of distribution (Vd) is approximately 0.2-0.3 L/kg, reflecting distribution primarily in extracellular fluid (plasma and interstitial space).
Oral: 0% (not absorbed); IV/IA/Intrathecal: 100% (administered directly into blood/CSF).
Not applicable (administered intravascularly); bioavailability is 100% for intravenous and intra-arterial routes as it does not undergo first-pass metabolism.
e GFR <30 m L/min/1.73m²: Administer with caution, consider prophylaxis with hydration and N-acetylcysteine. e GFR <15: Use only if diagnostic benefit outweighs risk of contrast-induced nephropathy. No specific dose reduction established; consider using lowest feasible volume.
No specific dose adjustment guidelines exist for Isovue-370 in renal impairment; however, caution is advised. In patients with GFR < 30 m L/min/1.73m², use lowest necessary dose and ensure adequate hydration. Hemodialysis may remove contrast; post-procedure dialysis can be considered.
No specific adjustments recommended for Child-Pugh class A, B, or C. Monitor renal function in patients with severe liver disease due to risk of hepatorenal syndrome.
No specific dose adjustment is required based on hepatic impairment; monitor renal function closely in patients with severe hepatic disease due to potential reduced clearance.
Neonates and infants: 1.5-2.0 m L/kg intravenously. Children: 1.0-2.0 m L/kg intravenously; maximum 2.0 m L/kg. For intra-arterial use, consult weight-based dosing guidelines.
Weight-based dosing: 1-2 m L/kg (3.7-7.4 mg I/kg) intravenously, not exceeding 3 m L/kg total dose. Adjusted based on imaging indication and patient factors; for CT, 1.5-2 m L/kg typical.
No specific dose adjustment required based on age alone. Assess renal function (e GFR) in elderly patients as age-related decline is common; follow renal adjustment guidelines. Ensure adequate hydration before and after administration.
Elderly patients may require lower doses due to age-related renal impairment and increased risk of contrast-induced nephropathy. Use the minimal effective dose and ensure adequate hydration. Individualize based on renal function.
Not for intrathecal use with ISOVUE-200 (iopamidol injection 41%) due to risk of severe adverse reactions including seizures, paralysis, and death.
No FDA black box warning.
Risk of severe hypersensitivity reactions including anaphylaxis; acute kidney injury in patients with pre-existing renal impairment; CNS adverse effects including seizures with intrathecal administration; thyroid dysfunction in patients with hyperthyroidism; contrast-induced nephropathy.
Risk of serious anaphylactic reactions; have emergency equipment available.,Acute renal toxicity, especially in patients with pre-existing renal impairment, diabetes, or dehydration.,Contrast-induced nephropathy; ensure adequate hydration.,Extravasation risk; monitor injection site.,Thyroid storm in patients with hyperthyroidism or thyroid nodules.,Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome).,Exacerbation of sickle cell disease.,Intrathecal use may cause neurotoxicity; avoid high doses.
Absolute: Hypersensitivity to iopamidol or any component; history of severe adverse reaction to iodinated contrast media; anuria or severe renal impairment (for intravascular use).,Relative: Pregnancy (only if clearly needed); lactation; multiple myeloma; pheochromocytoma; sickle cell disease.
History of hypersensitivity to iopamidol or other iodinated contrast agents.,Acute pancreatitis (for intrathecal use).,Intrathecal administration in patients with blood in CSF or increased intracranial pressure.,Anuria or severe renal impairment (relative).
No specific food interactions with ISOVUE-200. Patients are generally encouraged to hydrate with clear fluids before and after the procedure. There are no dietary restrictions. However, in patients with diabetes taking metformin, metformin should be withheld for 48 hours after contrast administration and only resumed after renal function is re-evaluated.
No specific food restrictions are required for this contrast agent. Maintain adequate hydration before and after administration. No known food-drug interactions.
Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essential. Second and third trimesters: no known teratogenicity; neonatal thyroid function monitoring recommended after exposure.
Iodinated contrast media, including iopamidol (ISOVUE-370), cross the placenta. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, due to potential fetal hypothyroidism from free iodide exposure, use in pregnancy only if clearly needed. First trimester: theoretical risk of fetal thyroid suppression; second and third trimesters: risk of neonatal hypothyroidism if high doses or repeated exposures. No documented congenital malformations in human data.
Minimal excretion into breast milk; M/P ratio not established. Iodinated contrast is poorly absorbed orally and poses negligible risk to nursing infant. Interruption of breastfeeding not required.
Iopamidol is excreted into human breast milk in minimal amounts (estimated infant dose <0.01% of maternal dose). M/P ratio not available. Because of low oral bioavailability and rapid milk clearance, breastfeeding can be continued without interruption; some sources suggest discarding milk for 12-24 hours post-procedure as a precaution.
No dose adjustment required in pregnancy; use lowest diagnostic dose. Monitor for volume overload in preeclampsia or compromised cardiac function.
No specific dose adjustment required for pregnancy based on pharmacokinetic changes. However, because of increased plasma volume and glomerular filtration rate in pregnancy, the elimination half-life may be slightly reduced. Use the lowest effective dose to minimize fetal iodide exposure. Adequate hydration is essential to prevent contrast-induced nephropathy.
ISOVUE-200 (iopamidol 41%) is a nonionic, low-osmolality iodinated contrast medium. It is indicated for intrathecal administration in myelography (lumbar, thoracic, cervical, total columnar) and for contrast enhancement in CT and angiocardiography. Key pearls: (1) Monitor renal function before administration due to risk of contrast-induced nephropathy; (2) Prehydrate patients with normal saline to reduce nephrotoxicity; (3) Have emergency equipment available for hypersensitivity reactions; (4) Avoid in patients with known iodine allergy or prior reaction to contrast; (5) Do not mix with other medications in the same syringe; (6) For intrathecal use, ensure proper patient positioning to minimize cephalad flow; (7) Use with caution in patients with sickle cell disease, pheochromocytoma, or hyperthyroidism.
Pre-warm contrast to body temperature to reduce viscosity and patient discomfort. Assess renal function (e GFR >30 m L/min/1.73m²) prior to administration; use lowest possible dose in patients with renal impairment. Have emergency equipment available for hypersensitivity reactions. For intravascular use, ensure adequate hydration before and after procedure. In diabetic patients taking metformin, withhold metformin for 48 hours post-contrast and monitor renal function.
Inform your doctor if you have ever had an allergic reaction to iodine, contrast dye, or any medications.,Tell your healthcare provider if you have kidney disease, diabetes, asthma, heart disease, or thyroid problems.,You may need to stop taking certain medications (e.g., metformin) before the procedure; follow your doctor's instructions.,You will be asked to drink plenty of fluids before and after the procedure to protect your kidneys.,During injection, you may feel warmth, a metallic taste in the mouth, or nausea; these are usually temporary.,Report any severe symptoms such as difficulty breathing, hives, swelling, or chest pain immediately.,After the procedure, you may resume normal diet unless otherwise instructed.,Breastfeeding women should pump and discard breast milk for 24 hours after contrast administration.
Inform your doctor if you have a history of allergic reactions to contrast media, asthma, or allergies.,Drink plenty of fluids before and after the procedure to help protect your kidneys.,Report any symptoms such as hives, itching, difficulty breathing, or swelling of the face/throat immediately.,If you are diabetic and take metformin, ask your doctor about temporarily stopping it.,You may feel warmth or a metallic taste during injection; these sensations are temporary.,Notify your doctor if you are pregnant, nursing, or have kidney disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-200 vs ISOVUE-370, answered by our medical review team.
ISOVUE-200 is a Contrast Media that works by Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.. ISOVUE-370 is a Contrast Media that works by Iodinated contrast agent that attenuates X-rays, providing radiographic contrast by increasing the density of vascular structures and tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-200 and ISOVUE-370 depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-200 is: Intravenous administration of 1.0-2.0 m L/kg (200 mg iodine/m L) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 m L total. Maximum recommended dose: 2.0 m L/kg.. The standard adult dose of ISOVUE-370 is: Intravenous injection of 50-200 m L of Isovue-370 (iopamidol 76% solution, 370 mg I/m L) for adults, administered as a bolus or infusion depending on imaging protocol. Typical dose for CT: 100-150 m L total volume.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-200 and ISOVUE-370 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-200 is classified as Category C. Iodinated contrast agents cross the placenta but have not been associated with teratogenic effects in humans. First trimester: theoretical risk from free iodide; avoid unless essen. ISOVUE-370 is classified as Category C. Iodinated contrast media, including iopamidol (ISOVUE-370), cross the placenta. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, due t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.